Results 1 to 10 of about 13,366 (181)
Pharmaceuticals, 2022 Nitroimidazole represents one of the most essential and unique scaffolds in drug discovery since its discovery in the 1950s. It was K. Maeda in Japan who reported in 1953 the first nitroimidazole as a natural product from Nocardia mesenterica with ...
Parvinder Pal Singh +2 more
exaly +3 more sources
Structure-enabled enhancement of potency in a metronidazole–benznidazole hybrid: design, synthesis, and evaluation of antitrypanosomal activity of a benzylamide-linked 5-nitroimidazole [PDF]
Frontiers in PharmacologyBenznidazole (1) remains the primary antiparasitic drug used clinically for Chagas disease, underscoring the need to discover novel treatments targeting Trypanosoma cruzi (T. cruzi) infection.
Afonso Santine M. M. Velez +8 more
doaj +2 more sources
Prevalence of Nitroimidazole-Refractory Giardiasis Acquired in Different World Regions, Sweden, 2008–2020 [PDF]
Emerging Infectious DiseasesTreatment-refractory giardiasis is an emerging clinical problem. Of 4,285 giardiasis cases identified during 2008–2020 in Stockholm, Sweden, 102 (2.4%) were nitroimidazole refractory. Among cases acquired in India, the percentage was high (64/545 [12%])
Karin A. Ydsten +3 more
doaj +2 more sources
Molecules, 2020 Novel transition metal complexes (Au, Pd, Pt) with berenil and 2-(1-methyl-5-nitroimidazol-2-yl)ethanol were obtained through two-step synthesis. The cytotoxicity assay against MCF-7 and MDA-MB-231 breast cancer cells revealed that novel platinum and ...
Izabela Prokop-Bielenia +2 more
exaly +3 more sources
Design, Synthesis and Anticancer Evaluation of Nitroimidazole Radiosensitisers
Molecules, 2023 The role of hypoxic tumour cells in resistance to radiotherapy, and in suppression of immune response, continues to endorse tumour hypoxia as a bona fide, yet largely untapped, drug target.
Lydia P. Liew +6 more
doaj +1 more source
Antioxidants, 2023 Cellular adaptations to hypoxia promote resistance to ionizing radiation (IR). This presents a challenge for treatment of head and neck cancer (HNC) that relies heavily on radiotherapy.
Faisal Bin Rashed +5 more
doaj +1 more source
Molecules, 2022 Nitro-containing compounds are a well-known class of anti-infective agents, especially in the field of anti-parasitic drug discovery. HAT or sleeping sickness is a neglected tropical disease caused by a protozoan parasite, Trypanosoma brucei.
Alireza Mousavi +5 more
doaj +1 more source
Niclosamide Is Active In Vitro against Mycetoma Pathogens
Molecules, 2021 Redox-active drugs are the mainstay of parasite chemotherapy. To assess their repurposing potential for eumycetoma, we have tested a set of nitroheterocycles and peroxides in vitro against two isolates of Madurella mycetomatis, the main causative agent ...
Abdelhalim B. Mahmoud +5 more
doaj +1 more source
Fexinidazole for Human African Trypanosomiasis, the Fruit of a Successful Public-Private Partnership
Diseases, 2022 After 100 years of chemotherapy with impractical and toxic drugs, an oral cure for human African trypanosomiasis (HAT) is available: Fexinidazole. In this case, we review the history of drug discovery for HAT with special emphasis on the discovery, pre ...
Sonja Bernhard +3 more
doaj +1 more source
Treatment of Giardiasis after Nonresponse to Nitroimidazole
Emerging Infectious Diseases, 2014 During January 2008–October 2013, a total of 12 cases of giardiasis at the Chaim Sheba and Shaare Zedek Medical Centers, Israel, did not respond to nitroimidazole; 83.3% were associated with travel and 33% with immunoglobulin deficiency.
Eli Schwartz +2 more
doaj +1 more source